7th Aug 2017 07:00
Horizon Discovery Group plc
Director/PDMR Shareholding
Cambridge, UK, 7 August 2017: Horizon Discovery Group plc (LSE: HZD) ("Horizon" or the "Company"), a global leader in the application of gene editing technologies, today announces that Richard Vellacott, Chief Financial Officer, was granted options under the Horizon Discovery 2014 Sharesave Scheme over Horizon Discovery Group plc ordinary shares of 1p each as detailed below:
| No. of shares under option | Option Exercise Price | Exercisable Date |
|
Richard Vellacott | 10,638 | £1.692 | 1 September 2020 |
|
|
|
|
|
|
In addition, Mr. Vellacott and Dr Darrin Disley, Chief Executive Officer, have exercised options under the Horizon Discovery 2014 Sharesave Scheme over Horizon Discovery Group plc ordinary shares of 1p each as a result of which their shareholdings have increased as detailed below:
| Number of options exercised and shares retained | Option Exercise Price | Exercise | No. of ordinary shares held in the Company following this transaction |
Richard Vellacott | 10,869 | £1.656 | 7 August 2017 | 37,869 |
Darrin Disley | 10,869 | £1.656 | 7 August 2017 | 725,392 |
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Richard Vellacott
| ||||
2 | Reason for the notification | |||||
a) | Position/status | Chief Financial Officer
| ||||
b)
| Initial notification /Amendment | Initial notification | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Horizon Discovery Group plc | ||||
b) | LEI | 213800L812B9NI5M3G89 | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a)
| Description of the financial instrument, type of instrument Identification code | Ordinary Shares of £0.01 each
ISIN: GB00BK8FL363 | ||||
b) | Nature of the transaction | 1. Grant of options 2. Exercise of options | ||||
c) | Currency | GBP | ||||
d) | Price(s) and volume(s) |
| ||||
e) | Aggregated information - Aggregated volume - Price |
N/A N/A | ||||
f) | Date of the transaction | 1. 4 August 2017 2. 7 August 2017 | ||||
g) | Place of the transaction | London Stock Exchange, AIM | ||||
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Dr Darrin Disley
| ||||
2 | Reason for the notification | |||||
a) | Position/status | Chief Executive Officer
| ||||
b)
| Initial notification /Amendment | Initial notification | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Horizon Discovery Group plc | ||||
b) | LEI | 213800L812B9NI5M3G89 | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a)
| Description of the financial instrument, type of instrument Identification code | Ordinary Shares of £0.01 each
ISIN: GB00BK8FL363 | ||||
b) | Nature of the transaction | Exercise of options | ||||
c) | Currency | GBP | ||||
d) | Price(s) and volume(s) |
| ||||
e) | Aggregated information - Aggregated volume - Price |
N/A N/A | ||||
f) | Date of the transaction | 7 August 2017 | ||||
g) | Place of the transaction | London Stock Exchange, AIM | ||||
- ENDS -
For further information from Horizon Discovery Group plc, please contact:
Horizon Discovery Group plc
Darrin Disley, Chief Executive Officer
Richard Vellacott, Chief Financial Officer
Chris Claxton, VP Investor Relations
Tel: +44 (0) 1223 655 580
Numis Securities Limited (Broker and NOMAD)
Michael Meade
Freddie Barnfield
Tom Ballard
Tel: +44 (0) 207 260 1000
Consilium Strategic Communications (Financial Media and Investor Relations)
Mary-Jane Elliott / Susan Stuart / Matthew Neal / Melissa Gardiner
Tel: +44 (0) 20 3709 5701
Email: [email protected]
About Horizon Discovery Group plc www.horizondiscovery.com
Horizon Discovery Group plc (LSE: HZD) ("Horizon"), is a leading global gene editing company that designs and engineers genetically-modified cells and then applies them in research and clinical applications that advance human health.
Horizon's core capabilities are built around its proprietary translational genomics platform, a highly precise and flexible suite of gene editing tools (rAAV, ZFN, CRISPR and Transposon) able to alter almost any gene sequence in human or mammalian cell-lines.
Horizon offers over 23,000 catalogue products and related research services, almost all of which are based on the generation and application of cell and animal models that accurately recapitulate the disease-causing genetic anomalies found in diseases like cancer. Horizon's commercial offering has been adopted by over 1,600 unique research organisations in over 50 countries as well as in the Company's own R&D pipeline to support a greater understanding of the genetic drivers of disease and the development of molecular, cell and gene therapies that can be prescribed on a personalised basis.
Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange's AIM market under the ticker "HZD".
Related Shares:
HZD.L